GBS Inc. initiates company name change to Intelligent Bio


Name change to more closely reflect the company’s expanding portfolio of smart, efficient, convenient and practical non-invasive and drug testing technologies and products –

– Harry Simeonidis appointed Chief Executive Officer –

– David Jenkins and Jason Isenberg appointed to the board –

NEW YORK, Oct. 26, 2022 (GLOBE NEWSWIRE) — GBS Inc. (Nasdaq: GBS), now Intelligent Bio Solutions Inc. (Nasdaq: IBSS) (the “Company”), a life sciences company developing real-time diagnostic solutions for patients and their primary point-of-care healthcare practitioners, announced today that the company has officially changed its name from GBS Inc. to Intelligent Bio Solutions Inc. and will begin trading under the new symbol “IBSS” on the Nasdaq effective at market open on Thursday, October 27, 2022.

So far, Steven Boyages has served as both Chairman and Interim CEO during this important transition phase. Given the growth and commercialization phase that IBSS plans to enter, the Board of Directors announces several new leadership appointments, including the position of Managing Director and two new members of the Intelligent Bio Board of Directors. Solutions.

Steven Boyages will remain Chairman of the Board and has reappointed Harry Simeonidis as Managing Director. Mr. Simeonidis has over 25 years of healthcare, pharmaceutical and life sciences experience in various leadership positions in Asia, Australia and New Zealand. Prior to joining Intelligent Bio Solutions, he was General Manager, Surgery, Asia Pacific, at GE Healthcare, where he oversaw the company’s significant market share expansion. Prior to that, Harry spent nine years as Chairman and CEO of GE Healthcare ANZ. Mr Simeonidis was also a non-executive director of Farmaforce Limited, a publicly traded contract sales organization serving the Australian pharmaceutical industry.

Finally, and following the acquisition of Intelligent Fingerprint, Intelligent Bio Solutions is pleased to announce the addition of David Jenkins and Jason Isenberg to its Board of Directors.

Mr. Jenkins has spent most of his career as an entrepreneur in the medical device industry and has founded numerous companies, including Catheter Precision, where he currently serves as CEO and Chairman of the Board of Catheter. He served as President and CEO of Arrhythmia Research Technology and oversaw the market introduction of Cardiolab, the first dual-monitor, 32-channel electrophysiology recording system. This technology was later acquired by General Electric and continues to be sold in the market today. Another of Mr. Jenkins’ companies, EP MedSystems, Inc., was sold to St. Jude Medical, Inc., now part of Abbott, for approximately $95.7 million in 2008. Mr. Jenkins has also founded and served as CEO of Transneuronix, Inc., a maker of implantable pacemakers for the treatment of weight loss, which was later sold to Medtronic for $267 million in 2005. Mr. Jenkins holds a a degree in accounting from the University of Kansas and a master’s degree in commerce from the University of Texas, Austin. He began his career in public accounting with Coopers and Lybrand.

With over 20 years of experience as an attorney, Jason Isenberg is currently Assistant General Counsel for RFA Management Company, LLC in Atlanta, Georgia, where he advises a broad portfolio of affiliates, trusts and foundations. , as well as their respective managers. , shareholders and boards of directors in areas such as corporate governance, corporate and real estate transactions, business operations, labor law and risk mitigation. Jason is recognized for successfully negotiating investment and corporate transactions totaling over $500,000,000. Jason’s prior experience includes working with and for several global law firms, focusing on the areas of construction and mass tort litigation. Jason received his Bachelor of Arts from the University of Maryland and his Juris Doctor from New England Law in Boston. Jason supports several Atlanta-based charities and is passionate about conservation.

About Intelligent Bio Solutions Inc.

Intelligent Bio Solutions Inc. is a life sciences company that develops real-time, non-invasive diagnostic and monitoring tests for patients and their primary healthcare practitioners. With its world’s first biosensor platform, Intelligent Bio Solutions is developing and launching urgently needed diagnostic tests to help people living with chronic disease. Additionally, through its recent acquisition of Intelligent Fingerprinting, the company is the global leader in advancing wearable drug abuse testing through fingerprint sweat analysis. The test is non-invasive, hygienic, quick and economical, and screens for recent use of opioids, cocaine, methamphetamines, benzodiazepines and marijuana. Collecting samples takes seconds, with results in ten minutes. A laboratory confirmation service is also available. The system has applications across many sectors, and customers include employers in safety-critical industries such as construction, transport and logistics companies, drug treatment organisations, as well as UK coroners.

Company Contact:

Alex Arzeno – Vice President of IR and Communications
GBS inc.

Investor contacts:

Tim McCarthy – General Manager
LifeSci Advisors, LLC

Media Contact:

Cheryl Billon
Communications by comma


Comments are closed.